



Paying for Value: Policy Options for Managing the Cost of PCSK9 Inhibitors and Other Specialty Drugs

October 5, 2015, 8:30AM – 12:30PM

The Pew Charitable Trusts

901 E St NW, Washington, DC 20004

| | |
|---|------------------------|
| Welcome | 8:30am-8:40am |
| State of Evidence for PCSK9 Inhibitors Presenter: Richard Kovacs, Professor & Clinical Director, Krannert Institute, Indiana University School of Medicine | 8:40am-8:50am |
| Assessing the Clinical Impact of Specialty Drugs Moderator: Emily Reese, Officer, The Pew Charitable Trusts Panelists: <ul style="list-style-type: none">• Richard Kovacs, Professor & Clinical Director, Krannert Institute, Indiana University School of Medicine• Eleanor Perfetto, Senior Vice President, National Health Council• Bill Sasiela, VP Program Direction, Regeneron | 8:50am-9:45am |
| Evidence, Pricing, Coverage, and Assessment of Value Moderator: Chuck Shih, Senior Officer, The Pew Charitable Trusts Panelists: <ul style="list-style-type: none">• Rena Conti, Assistant Professor, The University of Chicago• Josh Ofman, Senior Vice President, Global Value, Access and Policy, Amgen• Ebere Onukwugha, Associate Professor, University of Maryland• Steven Pearson, President, Institute for Clinical and Economic Review | 9:45am-10:45am |
| Break | 10:45am-11:00am |
| Seeking a More Rational Approach to Manage the Cost of Pharmaceuticals Moderator: Allan Coukell, Senior Director, The Pew Charitable Trusts Panelists: <ul style="list-style-type: none">• Kirsten Axelsen, Vice President Worldwide Policy, Pfizer• Richard Frank, Assistant Secretary for Planning and Evaluation, HHS• Steve Miller, Senior Vice President & Chief Medical Officer, Express Scripts• Debra Whitman, Executive Vice President, Policy, AARP | 11:00am-12:20pm |
| Closing Remarks | 12:20pm-12:30pm |